Nautilus Biotechnology logo

Nautilus Biotechnology

nautilus.bio

Nautilus Biotechnology develops the Voyager platform, which uses Iterative Mapping technology for accurate single-molecule quantification of proteins and proteoforms. Its products are designed for researchers in drug development, biomarker discovery, and exploratory biology to provide comprehensive views of the proteome and support deep biological insights. The organization aims to revolutionize biomedicine by unlocking the complexity of the proteome to positively impact global health.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2016
Employees
148
Stage
Public
Members see funding amounts.
.
Founders
Sujal Patel, Parag Mallick, PhD

Is this your organization? Claim it

Nautilus to Receive Up to $6M from ARPA-H SEEDS Consortium to Measure Proteoforms Driving Alzheimer’s and Ewing Sarcoma

Nautilus joins the ARPA-H-funded SEEDS consortium and expects up to $6 million to deploy its Voyager platform to measure proteoforms linked to Alzheimer’s disease and Ewing sarcoma, supporting a $51.7 million, four-year effort to predict misfolding of intrinsically disordered proteins and enable earlier detection and intervention. The consortium is co-led by the Buck Institute and Georgetown University and will combine protein science, AI, and computational approaches to study disease-causing protein behavior.

People

See all 4
  • Sujal Patel
    Sujal Patel Executive Officer, Director, Founder & CEO
  • Parag Mallick Founder & Chief Scientist
  • Anna Mowry Executive, Chief Financial Officer

Online